Fate Therapeutics Granted Exclusive License By The Regents of the to Stem Cell Modulators for Osteo-Regeneration |  |
|
Posted by BioSpace.com Featured News June 30th, 2009 .
| |
| No Comments |
LA JOLLA, Calif., July 1 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has acquired exclusive intellectual property rights covering small molecule compositions and methods for inducing bone formation from The Regents of the University of California. These proprietary osteogenic agents were developed by Farhad Parhami, Ph.D., professor of medicine at University of California, Los...
See other entries categorized in BioSpace, News, Syndication.
Print This Post
.
Subscribe by RSS or email. Connect with San Diego Biotech professionals by joining the SDBN and attending our next event.
Print This Post
.
Subscribe by RSS or email. Connect with San Diego Biotech professionals by joining the SDBN and attending our next event.
